These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17019708)

  • 1. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma.
    Salnikov AV; Heldin NE; Stuhr LB; Wiig H; Gerber H; Reed RK; Rubin K
    Int J Cancer; 2006 Dec; 119(12):2795-802. PubMed ID: 17019708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
    Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
    Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
    Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
    Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
    Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
    Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
    J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.
    Libertini S; Iacuzzo I; Perruolo G; Scala S; Ieranò C; Franco R; Hallden G; Portella G
    Clin Cancer Res; 2008 Oct; 14(20):6505-14. PubMed ID: 18927290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
    Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
    Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
    Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
    Photochem Photobiol Sci; 2007 Dec; 6(12):1275-83. PubMed ID: 18046482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.
    Smith NR; Baker D; Farren M; Pommier A; Swann R; Wang X; Mistry S; McDaid K; Kendrew J; Womack C; Wedge SR; Barry ST
    Clin Cancer Res; 2013 Dec; 19(24):6943-56. PubMed ID: 24030704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model.
    Bauer AJ; Patel A; Terrell R; Doniparthi K; Saji M; Ringel M; Tuttle RM; Francis GL
    Ann Clin Lab Sci; 2003; 33(2):192-9. PubMed ID: 12817624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
    Harada K; Supriatno ; Yoshida H; Sato M
    Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
    Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
    J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
    Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
    Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
    Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
    Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
    Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.